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Essential thrombocythemia (ET) is a clonal disorder of myeloid stem cells that causes thrombocytosis. As a result, 
ET can lead to vascular thrombosis and tissue ischemia; the association of coronary artery abnormalities such as 
myocardial infarction or unstable angina is rare. Here we describe a 45-year-old male patient with essential 
thrombocythemia who presented with unstable angina. Elective coronary angiography showed total occlusion of mid 
right coronary artery and mid left anterior descending coronary artery. ET was confirmed by a bone marrow biopsy; 
treatment was started with antiplatelet therapy including aspirin and clopidogrel along with cytostatic therapy with 
hydroxyurea and anagrelide. After the initiation of the treatment, the platelet count decreased to 20×104/μL. In 
addition, percutaneous coronary angioplasty was successfully performed with stent placement at the right coronary 
artery without hemorrhagic or thrombotic complications. 
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INTRODUCTION 
Essential thrombocythemia (ET) is a chronic myelo-
proliferative disorder characterized by clonal proliferation of 
magakaryocytes, which in turn leads to thrombocytosis1). 
Thrombosis and hemorrhage are typical complications in 
patients with the disease1). The rate of major thrombotic 
complications, such as acute coronary syndrome or cerebral 
ischemic attack has been reported, in one large study of 
patients with essential thrombocythemia, to be 7%2). There have 
been two prior reports of cases of acute coronary syndrome, as 
a complication of ET, successfully treated with PCI in 
combination with cytostatic therapy3, 4). Here we report 
successful coronary artery stent placement after cytostatic 
treatment, with hydroxyurea and anagrelide, in a patient with ET 
who presented with unstable angina.
CASE REPORT
A 45-year-old male was admitted to our hospital due to 
substernal chest discomfort on mild exertion, which occurred 
three weeks prior to presentation. The frequency and severity of 
his angina increased over time and the patient described a 
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Figure 2. Coronary angiogram. (A) Total occlusion of the mid RCA and 70% narrowing of proximal RCA is shown. (B) After successful 
coronary angioplasty with stents at the proximal RCA and mid RCA, the occlusion was recanalized. 
Figure 1. Bone marrow biopsy. Abundant number of megakary-
ocytes with atypical forms is shown, consistent with the diagnosis 
of essential thrombocythemia (H&E stain, ×200).
squeezing chest pain with an onset three days prior to 
presentation. The past medical history included hypertension, 
diagnosed three years ago, and smoking history of ten 
pack-years. There was no family history of coronary artery or 
hematologic disease. At the time of admission he was on 
aspirin and anti-hypertensive medications. On physical 
examination, the blood pressure was 130/80 mmHg and the 
heart rate was 70 beats per minute. The heart sounds were 
unremarkable with normal S1 and S2 sounds. The lungs were 
clear on auscultation. The electrocardiogram showed no 
ST-segment change, T wave inversion or pathologic Q waves 
suggestive of myocardial ischemia. No abnormality was found 
on chest roentgenogram. On complete blood count, the 
hemoglobin was 13.9 g/dL, white blood cell count was 9,400/L, 
and the platelet count was 106×104/μL. Electrolytes, renal and 
liver function tests were not remarkable. Levels of CK-MB and 
Troponin-T were within normal range. Total serum cholesterol 
was 161 mg/dL, triglyceride was 95 mg/dL and high-density 
lipoprotein was 39 mg/dL. Serum homocystein level was 12.7 
nmol/mL (reference range 5-15 nmol/mL), and hsCRP was 1.91 
mg/L (reference range <3 mg/L). Prothrombin time, activated 
partial thromboplastin time and fibrinogen level were within 
normal range. The iron profile was not remarkable. Bone 
marrow study showed a hypercellular marrow with markedly 
increased megakaryocytes, and a normal myeloid/erythroid ratio 
(Figure 1). Chromosomal analysis of bone marrow cells 
revealed a normal 46, XY karyotype with no evidence of bcr/abl 
rearrangement. Liver and spleen were not enlarged on 
sonogram images. An elective coronary angiography, two days 
after admission, showed total occlusion at the mid right 
coronary artery (RCA) with well-developed collaterals from 
proximal RCA to PD and PL branches. In addition, there was 
diffuse irregular, up to 70%, luminal narrowing with haziness 
noted at the proximal RCA. The left coronary angiography 
showed a 40% luminal narrowing at the mid left anterior 
descending artery (LAD). The echocardiography, performed 
three days after admission, showed no regional wall motion 
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abnormality with about 60% of left ventricular ejection fraction. 
On color Doppler imaging, there was no significant valvular 
stenosis or regurgitation noted. There was a relaxational 
abnormality observed in the diastolic filling pattern. The patient 
was taking aspirin 100 mg/day, clopidogrel 75 mg/day, atenolol 
25 mg/day, diltiazem 90 mg/day and nicorandil 15 mg/day from 
the day of admission. The chest pain was controlled by medical 
treatment; therefore, we decided to postpone coronary artery 
intervention until the platelet count reached a normal level. 
Treatment with hyroxyurea 500 mg/day and anagrelide HCl 1 
mg/day was started as cytostatic therapy. The platelet count 
was normalized (23×104/μL) five weeks after initiation of 
cytostatic therapy, and coronary artery intervention was then 
performed. The totally occluded mid RCA lesion was thought to 
be a chronic total occlusion because of the presence of good 
collateral flow from the proximal RCA. We thought that the 
proximal RCA, stenotic lesion with haziness, resulted from a 
plaque rupture resulting in an occlusive thrombus, and caused 
the ischemic symptoms that the patient presented with. Two 
coronary stents were placed at the proximal and mid RCA. No 
residual stenosis was observed after the procedure (Figure 2). 
The LAD lesion was not treated. . The patient was discharged 
two days after the procedure without any hemorrhagic or 
thrombotic complication; he remained on aspirin, clopidogrel, 
hydroxyurea, and anagrelide. The patient was free of symptoms 
for six months during the follow-up period, and his platelet 
count remained within normal range. 
DISCUSSION
ET occasionally presents with arterial and/or venous 
thrombosis, and less frequently with hemorrhagic complications. 
These thrombotic and vascular complications are the main 
causes of death in patients with ET1, 5, 6). Although ET may 
cause vascular thrombosis and tissue ischemia, coronary artery 
involvement, with acute coronary syndrome, is very uncommon. 
Only about 21 such cases have been described in the medical 
literature, and four of these cases were reported to be treated 
with coronary angioplasty and stent placement3, 4, 7, 8). 
Among the four patients with an acute coronary syndrome 
complication of ET, two patients received percutaneous 
coronary angioplasty with stent placement without any cytostatic 
therapy. These patients suffered from the complication of stent 
thrombosis after the procedure7, 8). The other two had unstable 
angina as a complication of ET and they received percutaneous 
angioplasty with stent placement along with cytostatic and 
antiplatelet therapy3, 4). Their post-procedure course was 
uneventful, and they were discharged without any thrombotic 
complication.
With advancement and availability of coronary angioplasty 
techniques, coronary intervention with stent placement, for ET 
patients, is becoming common. However, as described above, 
the rate of in stent thrombosis is very high (two out of two 
cases) in patients who were not given cytostatic and antiplatelet 
agents. These facts suggest that aggressive inhibition of platelet 
aggregation and production, before and after angioplasty, might 
play an important role in the treatment of coronary artery 
diseases in patients with ET. 
There are two forms of cytostatic therapy, cytostatic agents 
and platelet apheresis Prompt and aggressive use of 
hydroxyurea is warranted in any patient with who has active 
cardiovascular ischemia6). The recommended starting dose is 1
5～30 mg per kilogram of body weight per day; however, the 
dose should be adjusted to achieve optimal control of 
thrombocytosis without the complications of anemia or 
leucopenia9-11). The appropriate time to perform coronary 
angioplasty, with stent placement, should be based on individual 
patient presentation. It is reasonable to perform PCI after the 
platelet count is less than 40×104/μL, as long as recurrent 
ischemia can be prevented with medical treatment11). Mitsunori 
et al. reported a successful PCI with stent insertion after three 
weeks of cytostatic therapy with 1,500 mg/day of hydroxyurea. 
However, we administered 400 mg/day of hydroxyurea for five 
weeks in our case.
In patients with acute myocardial infarction or unstable 
angina/non-ST elevation myocardial infarction, primary PCI or 
early invasive intervention must proceed without hesitation 
regardless of the patients’ platelet counts. In an emergency 
situation, platelet apheresis can provide effective and relatively 
safe reduction of platelet counts in a short time11). Tansel et al. 
reported a case with successful platelet apheresis after PCI in 
patients with ET7). As the beneficial effect of platelet apheresis 
is generally short-lived it is essential to initiate cytostatic therapy 
at the same time11). 
Anagrelide and alpha-interferon are additional cytostatic 
agents. A report from Sandra et al., and our own experience, 
suggests that no thrombotic complication with anagrelide use 
along with coronary artery interventions. The antithrombotic 
effect of these agents has never been proven; moreover their 
use is limited in certain situations i.e. alpha interferon is 
contraindicated in thyroid disease or in patients with psychiatric 
disorders; anagrelide is contraindicated in patients with severe 
cardiovascular disease and used with caution in patients who 
have documented coronary ischemia9). 
Antiplatelet agents, aspirin and adenosin dephosphate 
inhibitor are usually given to the patients who have PCI; aspirin 
appears to be beneficial also in patients with ET. The incidence 
of thrombosis was significantly reduced following aspirin 
administration particularly at a lower dose (100 mg/d)12). 
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However, the proper maintenance dose, duration of treatment 
and benefit of aspirin and adenosin dephosphate have to be 
further defined in future clinical investigations in patients with 
coronary artery disease and ET. It is probable that the platelet 
glycoprotein IIb/IIIa receptor inhibitor plays a crucial role in 
treating ET-associated ischemic syndromes with coronary 
thrombus. There is one case report documenting the successful 
use of abciximab with PCI in ET-associated coronary 
thrombosis13). 
In conclusion, antiplatelet cytostatic treatment played a critical 
role in coronary angioplasty with stent placement in patients 
with ET and coronary artery disease. Further clinical trials are 
needed to evaluate the efficacy of these agents in coronary 
artery disease with ET.
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